Sign In
Buy LXRX
$2.31
-0.0300 (-1.28%)
At Close: Jul 31, 2026
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
11:35am, Tuesday, 24'th Mar 2026
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
08:00am, Tuesday, 24'th Mar 2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
07:30am, Monday, 23'rd Mar 2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
01:58am, Sunday, 15'th Mar 2026
Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of ki
Lexicon Pharmaceuticals Q4 Earnings Call Highlights
04:48am, Saturday, 07'th Mar 2026
Lexicon Pharmaceuticals (NASDAQ: LXRX) outlined progress across three late-stage programs and reported sharply lower operating expenses during its fourth-quarter and full-year 2025 earnings call held
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
05:15pm, Thursday, 05'th Mar 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
06:59am, Thursday, 05'th Mar 2026
Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 rea
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
04:01pm, Tuesday, 03'rd Mar 2026
THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
08:30am, Thursday, 26'th Feb 2026
THE WOODLANDS, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter 2025 financial results on Thursday, Mar
Raymond Debbane Purchases 100,000 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock
04:44am, Wednesday, 25'th Feb 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) Director Raymond Debbane acquired 100,000 shares of the business's stock in a transaction on Friday, February 20th. The shares were purch
GSA Capital Partners LLP Sells 1,627,753 Shares of Lexicon Pharmaceuticals, Inc. $LXRX
04:16am, Wednesday, 18'th Feb 2026
GSA Capital Partners LLP lessened its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) by 57.5% in the third quarter, according to its most recent filing with the Securities and Exchang
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
05:17pm, Friday, 06'th Feb 2026
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offer
Invus Global Management, Llc Purchases 1,538,462 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock
04:40am, Friday, 06'th Feb 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) Director Invus Global Management, Llc bought 1,538,462 shares of the firm's stock in a transaction that occurred on Monday, February 2nd.
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
02:50am, Friday, 30'th Jan 2026
THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offer
